Zentalis Pharmaceuticals, Inc.
For the period ended Jun 30, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 6, 2025
ZNTL$1.74+1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| ExhibitNumber · Description · Incorporated by Reference | ||||||
|---|---|---|---|---|---|---|
| Form · File No. · Exhibit · FilingDate · Filed/Furnished Herewith | ||||||
| 2.1 | Plan of Conversion Converting Zentalis Pharmaceuticals, LLC (a Delaware limited liability company) into Zentalis Pharmaceuticals, Inc. (a Delaware corporation) | 10-Q | 001-39263 | 2.1 | 05/15/2020 | |
| 2.2 | Certificate of Conversion Converting Zentalis Pharmaceuticals, LLC (a Delaware limited liability company) into Zentalis Pharmaceuticals, Inc. (a Delaware corporation) | 10-Q | 001-39263 | 2.2 | 05/15/2020 | |
| 3.1 | Certificate of Incorporation of Zentalis Pharmaceuticals, Inc. | S-8 | 333-237593 | 4.1 | 04/07/2020 | |
| 3.2 | Certificate of Amendment to Certificate of Incorporation of Zentalis Pharmaceuticals, Inc., dated June 16, 2023 | 8-K | 001-39263 | 3.1 | 06/16/2023 | |
| 3.3 | Amended and Restated Bylaws of Zentalis Pharmaceuticals, Inc. | 8-K | 001-39263 | 3.1 | 02/15/2024 | |
| 10.1† | Release Agreement, dated April 25, 2025 between Zentalis Pharmaceuticals, Inc., Zeno Management, Inc., and Mark Lackner, Ph.D. | * | ||||
| 10.2† | Consulting Agreement, dated April 25, 2025 between Zentalis Pharmaceuticals, Inc. and Mark Lackner, Ph.D. | * | ||||
| 31.1 | Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a). | * | ||||
| 31.2 | Certification of Principal Financial Officer pursuant to Exchange Act Rule 13a-14(a). | * | ||||
| 32.1 | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350. | ** | ||||
| 32.2 | Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350. | ** | ||||
| 101.INS | Inline XBRL Instance Document | * | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | * | ||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | * | ||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | * | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | * | ||||
| ExhibitNumber | Description | Incorporated by Reference | ||||
| Form | File No. | Exhibit | FilingDate | Filed/Furnished Herewith | ||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | * | ||||
| 104 | Cover Page Interactive Data file (formatted as inline XBRL and contained in Exhibit 101) | * | ||||
- Filed herewith.
** Furnished herewith.
† Portions of this exhibit (indicated by asterisks) have been redacted in compliance with Regulation S-K item 601(b)(10)(iv).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.